Significance of predischarge BNP on one-year outcome in decompensated heart failure--comparative study with

Yoko Hamada1, Nobuaki Tanaka, Kazuya Murata

  • 1Division of Cardiovascular Medicine, Department of Medical Bioregulation, Yamaguchi University School of Medicine, Yamaguchi, Japan.

Journal of Cardiac Failure
|February 11, 2005
PubMed

Insights

Predischarge B-type natriuretic peptide (BNP) levels, not admission levels, predict rehospitalization for congestive heart failure (CHF) within a year. Etiology did not impact BNP or echo-Doppler index prognosis.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Management

Background:

  • Congestive heart failure (CHF) prognosis relies on cardiac natriuretic peptides and echo-Doppler indexes.
  • Etiology-specific prognostic differences in CHF require further investigation.
  • Assessing transmitral flow (TMF) and B-type natriuretic peptide (BNP) in ischemic vs. nonischemic CHF.

Purpose of the Study:

  • Evaluate the prognostic value of TMF and BNP in acutely decompensated CHF.
  • Compare prognostic indicators in ischemic (old myocardial infarction - OMI) and nonischemic (idiopathic dilated cardiomyopathy - DCM) etiologies.
  • Determine if admission or predischarge measurements are more predictive of rehospitalization.

Main Methods:

  • Studied 52 chronic CHF patients (31 OMI, 21 DCM) during acute decompensation.
  • Performed echo-Doppler studies and measured plasma BNP on admission and predischarge.
  • Monitored rehospitalization rates over 1 year, comparing patients with stable courses (S group) to those rehospitalized (R group).

Main Results:

  • Admission TMF and BNP levels were similar between DCM and OMI groups, and between R and S groups.
  • Predischarge BNP levels were significantly higher in the rehospitalized (R) group compared to the stable (S) group.
  • Kaplan-Meier analysis confirmed predischarge BNP's influence on 1-year prognosis.

Conclusions:

  • Predischarge BNP levels, rather than admission levels, are predictive of 1-year rehospitalization risk in CHF.
  • No significant differences were observed between BNP and echo-Doppler indexes concerning CHF etiology (OMI vs. DCM).
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...